, Volume 52, Supplement 3, pp 39–47 | Cite as

Pharmacology and Clinical Experience with Tramadol in Osteoarthritis

  • Warren A. Katz


Tramadol is a centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states. Unlike other centrally acting analgesics, it exerts a dual action by binding to the opioid receptor site in the central nervous system and by weakly inhibiting the reuptake of biogenic amines. Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration. The recommended dosage is 50 to 100mg every 4 to 6 hours; however, regular administration is an alternative, particularly for chronic pain states such as osteoarthritis, where the use of the recently developed sustained release formulation may represent an important advantage. Published studies specifically evaluating the use of tramadol in this disease support its effectiveness. Nausea, drowsiness, constipation, dizziness, and sweating have been reported in association with tramadol use. Nausea occurs early in the course of administration, and may be reduced by slowly titrating the dose of tramadol against response. Tramadol would appear to be particularly useful in the elderly population affected by osteoarthritis because, unlike nonsteroidal anti-inflammatory drugs, it does not aggravate hypertension or congestive heart failure, nor does it have the potential to cause peptic ulcer disease. Compared with narcotics, tramadol does not induce significant respiratory depression, constipation, or have significant abuse potential.


Osteoarthritis Adis International Limited Ibuprofen Paracetamol Tramadol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moskowtiz RW. Osteoarthritis. In: Katz WA, editor. Diagnosis and management of rheumatic diseases. Philadelphia: JB Lippincott, 1988: 569–81.Google Scholar
  2. 2.
    National Pain Survey, Lewis Harris and Associates, Inc., 1994Google Scholar
  3. 3.
    Bradley JD, Brandt KD, Katz BP, et al. Comparison of an anti- inflammatory dose of ibuprofen, analgesic dose of ibuprofen and acetaminophen in the treatment of osteoarthritis of the knee. N Engl J Med 1991; 325: 87–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Simon L. Toxicities of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1992; 4: 301–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Friderichs E, Felgenhuer F, Jongschaap P, et al. Pharmakologische Untersuchungen zur Analgesie, Abhängigkeits und Toleranzentwicklung von Tramadol, einem stark wirkenden Analgetikum. Arzneimittelforschung/Drug Res 1978; 28: 122.Google Scholar
  6. 6.
    Barth H, Durra S, Giertz H, et al. Long-term administration of the centrally acting analgesic tramadol did not induce dependence or tolerance [abstract 439]. Pain 1987; Suppl. 4: S231CrossRefGoogle Scholar
  7. 7.
    Keup W. Missbrauchsmuster bei Abhangigkeit von Alkohol, Medikamenten und Drogen: Frühwarnsystem-daten für die Bundesrepublik Deutschland 1976–1990. Lambertus, Freiberg im Breisgau, 1993Google Scholar
  8. 8.
    Collart L, Luthy C, Dayer P. Multimodal analgesic effect of tramadol [abstract]. Clin Pharmacol Ther 1993; 53: 223.Google Scholar
  9. 9.
    Raffa RB, Nayak RK, Liao S, et al. Mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother 1995; 6: 485–97.Google Scholar
  10. 10.
    Grond S, Meuser T, Zech D, et al. Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia. Pain 1995; 62: 313–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Liao S, Hill JF, Nayak RK. Pharmacokinetics of tramadol following single and multiple oral doses in man [abstract]. Pharm Res 1992; 9 Suppl. 10: S308.Google Scholar
  12. 12.
    Lintz W, Barth H, Osterloh G, et al. Bioavailability of enterai tramadol formulations. 1st communication: capsules. Arzneimittelforschung/Drug Res 1986; 36: 1278–83.Google Scholar
  13. 13.
    Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Invest 1992; 70: 708–10.CrossRefGoogle Scholar
  14. 14.
    Lintz W, Erlacin S, Frankus E, et al. Biotransformation of tramadol in man and animal. Arzneimittelforschung/Drug Res 1981; 31: 1932–43.Google Scholar
  15. 15.
    Suvonnakote T, Thitadilok W, Atisook R, et al. Pain relief during labour. J Med Assoc Thai 1986; 69: 575–80.PubMedGoogle Scholar
  16. 16.
    ULTRAM® (tramadol HCl) prescribing information. Raritan, NJ: McNeil Pharmaceutical, 1995Google Scholar
  17. 17.
    Grünenthal, data on file. Report no. FO-PK 163/1Google Scholar
  18. 18.
    Budd K. Chronic pain: challenge and response. Drugs 1994; 47 Suppl. 1: 33–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Grünenthal, data on file. Report no. FO-PK 240Google Scholar
  20. 20.
    Grünenthal, data on file. Report no. FO-PK 241Google Scholar
  21. 21.
    Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung/Drug Res 1988; 38: 877–80.Google Scholar
  22. 22.
    TRAMAL® (Tramadol Hcl). Prescribing information. Grünenthal GmbH, Stolberg, GermanyGoogle Scholar
  23. 23.
    RW Johnson Pharmaceutical Research Institute, data on fileGoogle Scholar
  24. 24.
    Sunshine A, Alaska E, Slafta J. A comparison of the analgesic effects of tramadol (Upjohn U-26, 225A and propoxyphene HC1). Bulletin. Problems of drug dependence, National Academy of Sciences, National Research Counsel, Washington, DC, 1970, 6901–4Google Scholar
  25. 25.
    Sunshine A, Olson NZ, Zighelboim I, et al. Analgesic oral efficacy of tramadol hydrochloride in post-operative pain. Clin Pharmacol Ther 1992; 51: 740–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Sunshine A. New clinical experience with tramadol. Drugs 1994; 47 Suppl. 1: 8–18.PubMedCrossRefGoogle Scholar
  27. 27.
    Gobel H, Stadler Th. Treatment of pain due to postherpetic neuralgia with tramadol. Results of an open, parallel pilot study versus clomipramine with or without levomepromazine. Clin Drug Invest 1995; 10: 208–14.Google Scholar
  28. 28.
    Rauck RL, Ruoff GE, McMillen JI. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res 1994; 55: 1417–31.CrossRefGoogle Scholar
  29. 29.
    Roth SH. Safety and efficacy of tramadol HC1 in breakthrough osteoarthritis pain. Rheumatol Eur 1995; 24 Suppl. 12: 310.Google Scholar
  30. 30.
    Bird HA, Hill J, Stratford GC, et al. A double-blind cross-over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. J Drug Dev Clin Pract 1995; 7: 181–8.Google Scholar
  31. 31.
    Rousi T, Pohjola R, Martio J. Tramadol in the treatment of osteoarthritic pain: a double-blind, crossover study versus dextropropoxyphene. XIIth European Congress on Rheumatology: Jun 30–Jul 6: Budapest, Hungary: 1991Google Scholar
  32. 32.
    Pavelka K. Functional outcome and joint pain is improved in osteoarthritis patients receiving an NSAID or a centrally acting analgesic. Ann Rheum Dis. In pressGoogle Scholar
  33. 33.
    Cossmann M, Wilsmann KM. Parenteral administration of tramadol (Tramai®): an open clinical trial to assess the effect and side effects after single parenteral application. Münch Med Wochenschr 1988; 130: 633–6.Google Scholar
  34. 34.
    Cossmann M, Wilsmann KM. Treatment of prolonged pain: assessment of the efficacy and safety of repeated administration of tramadol (Tramai®). Münch Med Wochenschr 1987; 129: 851–4.Google Scholar
  35. 35.
    Cossmann M, Wilsmann KM. Effect and side effect of tramadol: an open phase IV study with 7198 patients. Therapiewoche 1987; 37: 3475–85.Google Scholar
  36. 36.
    Lee CR, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313–40.PubMedCrossRefGoogle Scholar
  37. 37.
    Riedel F, von Stockhausen HB. Severe cerebral depression after intoxication with tramadol in a 6-month old infant. Eur J Clin Pharmacol 1984: 26: 631–2PubMedCrossRefGoogle Scholar
  38. 38.
    Cossmann M, Kohnen C. General tolerability and adverse event profile of tramadol hydrochloride. Rev Contemp Pharmacother 1995; 6: 513–31.Google Scholar
  39. 39.
    Dalgin PH. Use of tramadol in chronic pain. Clin Geriatr 1995; 3: 17–30.Google Scholar
  40. 40.
    Kayser V, Besson JM, Guilbaud G. Effects of the analgesic agent tramadol in normal and arthritic rats; comparison with the effects of different opioids, including tolerance and cross tolerance to morphine. Eur J Pharmacol 1991; 195: 37–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacologic comparison of tramadol and morphine. Drug Alcohol Depend 1991; 27: 7–17.PubMedCrossRefGoogle Scholar
  42. 42.
    Richter W, Barth H, Flohe L, et al. Clinical investigation of the development of dependence during oral therapy with tramadol. Arzneimittelforschung/Drug Res 1985; 35: 1742–4.Google Scholar
  43. 43.
    Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28: 686–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Brandt KD. Should osteoarthritis be treated with nonsteroidal antiinflammatory drugs? Rheum Dis Clin 1993; 19: 697–712Google Scholar
  45. 45.
    Todd PA, Clissold SP. Naproxen. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases in pain states. Drugs 1990; 40: 91–137.PubMedCrossRefGoogle Scholar
  46. 46.
    Myers SL, Brandt KD, Ehrlich JW, et al. Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 1990; 17: 1662–9.PubMedGoogle Scholar
  47. 47.
    Jones AC, Berman P, Doherty M. Nonsteroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol 1992; 31: 45–8PubMedCrossRefGoogle Scholar
  48. 48.
    Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1335–40.Google Scholar
  49. 49.
    Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1341–6.CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Warren A. Katz
    • 1
  1. 1.University of Pennsylvania Health SystemsPhiladelphiaUSA

Personalised recommendations